Study boosts Cymbalta's pain app

Eli Lilly now has another arrow in its new-Cymbalta-indication quiver. A study released at the European Federation of Neurological Societies found that 31 percent of patients taking the antidepressant for back pain said their discomfort dropped by half, compared with just 19 percent using placebo. Relief for the Cymbalta patients came in the first week and continued through the 13-week acute phase of the study.

As you know, in May Lilly asked the FDA to allow Cymbalta to be marketed as a chronic pain drug. The company has been studying it as a treatment for fibromyalgia and osteoporosis pain, as well as back pain.

If Lilly gets the FDA go-ahead, it would be another boost to a drug that's already a big contributor to Lilly's bottom line. Cymbalta's second-quarter sales alone jumped by 26 percentn to $654 million.

- read the CNN Money news

Suggested Articles

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Intent-driven audiences are inspired to make health-improving changes after a positive online experience. Find out what they’re driven to do.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.